Please provide your email address to receive an email when new articles are posted on . A 0.5 mg daily dose of oral dutasteride was superior to minoxidil and finasteride in total hair count at 24 ...

This article was reviewed by Knox Beasley, MD. If you’re thinking of switching from finasteride to dutasteride for hair loss, there are some critical things to know. Only two medications are approved ...

After months (or years!) of taking finasteride, you’ve seen some progress. Your hairline is holding steady, but regrowth seems to have stalled. Enter dutasteride: a stronger cousin of finasteride that ...

Please provide your email address to receive an email when new articles are posted on . Mesotherapy with dutasteride was effective and associated with no serious side effects in a cohort of patients ...

Hair loss can be traumatic and, unfortunately, extremely common. But a New Jersey doctor says he has a new treatment. For about a year, East Brunswick dermatologist Dr. Sandy Milgraum has been ...

A four-year study of more than 8,000 men between the ages of 50 to 75 who had an elevated risk for developing prostate cancer found that those who took the drug dutasteride (sold as Avodart) were less ...

Dutasteride treatment for benign prostatic hyperplasia (BPH) is associated with a significant increase in serum testosterone and a significant decrease in BMI among men with relatively lower baseline ...

BERLIN—Regardless of clinical parameters affecting prostate cancer risk (PCa), men who took the dual 5α-reductase inhibitor dutasteride for two to four years reduced their incidence of ...

To date, the relative efficacy of the 3 treatments—minoxidil and 5α reductase inhibitors (5-ARIs) finasteride and dutasteride—has remained largely unknown. In a new study, researchers shared their ...

Happy Head has made waves in the hair loss industry with a range of products customized to different stages and causes of hair loss. With its focus on scientifically backed, FDA-approved ingredients ...

Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other ...